Calcipotriene, Betamethasone Dipropionate Gel Approved in Europe for Scalp Psoriasis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Calcipotriene, Betamethasone Dipropionate Gel Approved in Europe for Scalp Psoriasis

NEW YORK -- August 20, 2008 -- Calcipotriene 0.005% plus betamethasone dipropinate 0.064% (Xamiol) gel has been approved in Europe for the treatment of scalp psoriasis.

In clinical studies, the gel proved effective in the treatment of chronic psoriasis occurring in the scalp. Results showed that 8 out of 10 patients felt their disease was under control by the end of treatment.

The gel will be available in Europe later this year.

SOURCE: Leo Pharma

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities